Clinical Trial Search

Primary: Walking Speed During Timed 25-foot Walk — 0.3342; 0.4745; 0.4593; 0.1743 feet/second

Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants

Primary: ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living) — 3.1; 4.9 score on a scale — p=0.003

Primary: Number of Patient With Lack of Objective Clinical Improvement — 0 Participants

Primary: Annualized Relapse Rate Before Cetirizine — 0.4; 0.1 relapses per year

Primary: Number of Participants With Survival — 66; 64 Participants

Primary: Graded and Redefined Assessment of Strength, Sensibility and Prehension Test (GRASSP Test) — 4.5; 19.4 score change before and after — p=<0.000

Primary: Electromyography — 0.00017507; 0.00006740 volts

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Number of Participants With Infection — 4; 3 Participants

Primary: Number of Adverse Safety Events During Hospitalization — 0 adverse safety events

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Overall Survival — 88.0 percentage of participants

Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Arm and Hand Function as Assessed by Score on the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) — 64.9; 58.3 score on a scale

Primary: Compare the Average Total Improvement Scores at Visits 2 Through 7 During the 6-month Treatment Period Between the Treatment and Placebo Arms — 26.4; 29.3 score on a…

Primary: Number of Participants Achieving International Myositis Assessment and Clinical Studies Definition of Improvement (IMACS DOI) at Week 24 Without Rescue — 42; 31…

Primary: Event-Free Survival Probability During the 5 Years After Transplant — 0.692 Probability

Primary: Baseline Expanded Disability Status Score (EDSS) — 3.5 units on a scale

Primary: Percent Change in Hmax — 27.85; 8.43; -4.91; 16.20 percent change in Hmax

Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds

Primary: Clinical Safety of TIV Vaccine — 4; 0; 0; 0 Participants

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci

Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms

Primary: Response Rate During Randomized Phase — 3; 1; 5; 2 Participants — p=0.60

Primary: Safety of Using TTNS at Home Daily as Indicated by Number of Adverse Events Recorded in Bladder Diary — 0 adverse events

Primary: The Time From Randomization to the First Demyelinating Event (Acute or Development of an Initial Symptom Resulting in a Progressive Clinical Course) — 89.69; 77.81 weeks

Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318

Primary: Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product — 71; 46; 1; 4 Participants